Abstract

At OSUCCC, the stimulus for protocol development comes from the Disease Specific Committees. Priorities for accrual to studies are also set by the Committees. Individuals seek design advice and formatting help from the Interdisciplinary Oncology Unit in the preparation of proposals for submission to both the Scientific Review Committee (SRC) of the Center, and the Institutional Review Board (IRB), which are separate entities. Investigators can choose to send their proposal either the SRC or the IRB first. Investigators may appear to defend their study and outside consultants are appropriate. The SRC monitors the progress of each institutional study for accrual on a regular basis. There are clearly defined stopping rules and the SRC appears to have the authority to implement them. The quality of data is audited by an Audit Committee whose minutes were supplied for review to the site visitors. This committee meets monthly and reviews a random selection of charts for protocol compliance. The Institution is in the process of establishing an office to monitor clinical studies that will have overarching responsibilities to assure quality of data.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-21
Application #
3729047
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
21
Fiscal Year
1995
Total Cost
Indirect Cost

  Institution

Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210

  Publications

Nguyen, Phuong; Wuthrick, Evan; Chablani, Priyanka et al. (2018) Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 41:140-146
Elchuri, Sailaja V; Rajasekaran, Swetha; Miles, Wayne O (2018) RNA-Sequencing of Primary Retinoblastoma Tumors Provides New Insights and Challenges Into Tumor Development. Front Genet 9:170
Reiff, Sean D; Muhowski, Elizabeth M; Guinn, Daphne et al. (2018) Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood 132:1039-1049
Nabar, Gauri M; Mahajan, Kalpesh D; Calhoun, Mark A et al. (2018) Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366
Tang, Xiaowen; Yang, Lin; Li, Zheng et al. (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8:1083-1089
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539
Rolfo, Christian; Mack, Philip C; Scagliotti, Giorgio V et al. (2018) Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol 13:1248-1268
Ren, Yulin; Gallucci, Judith C; Li, Xinxin et al. (2018) Crystal Structures and Human Leukemia Cell Apoptosis Inducible Activities of Parthenolide Analogues Isolated from Piptocoma rufescens. J Nat Prod 81:554-561
McDonald, J Tyson; Kritharis, Athena; Beheshti, Afshin et al. (2018) Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. Oncotarget 9:22693-22702
Reiter, Paul L; Shoben, Abigail B; McDonough, Deborah et al. (2018) Results of a Pilot Study of a Mail-Based HPV Self-Testing Program for Underscreened Women from Appalachian Ohio. Sex Transm Dis :

Showing the most recent 10 out of 2602 publications